Advertisement
Advertisement
TGTX
TG Therapeutics, Inc.
39.50
USDSponsored
-1.29
-3.16%
May 15, 15:59 UTC -4
Closed
After-Market
39.31
-0.19
-0.49%
TGTX Earnings Reports
Positive Surprise Ratio
TGTX beat 12 of 42 last estimates.
29%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$231.11M
/$0.35
Implied change from Q1 26 (Revenue/ EPS)
+12.78%
/+94.44%
Implied change from Q2 25 (Revenue/ EPS)
+63.74%
/+105.88%
TG Therapeutics, Inc. earnings per share and revenue
On May 06, 2026, TGTX reported earnings of 0.18 USD per share (EPS) for Q1 26, missing the estimate of 0.30 USD, resulting in a -40.10% surprise. Revenue reached 204.92 million, compared to an expected 200.75 million, with a 2.08% difference. The market reacted with a +16.26% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of 0.35 USD, with revenue projected to reach 231.11 million USD, implying an increase of 94.44% EPS, and increase of 12.78% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Eton Pharmaceutcials, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
$0.09
Actual
$0.05
Surprise
-45.53%
CorMedix Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
$0.37
Actual
$0.43
Surprise
+15.59%
Autolus Therapeutics plc - ADR
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.27
Surprise
-2.94%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+217.65%
Alpha Cognition Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.39
Actual
-$0.37
Surprise
+6.19%
Dogwood Therapeutics, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.15
Surprise
+42.70%
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
Elutia Inc. Class A Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
FAQ
What were TG Therapeutics, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, TG Therapeutics, Inc. reported EPS of $0.18, missing estimates by -40.1%, and revenue of $204.92M, 2.08% above expectations.
How did the market react to TG Therapeutics, Inc.'s Q1 2026 earnings?
The stock price moved up 16.26%, changed from $36.10 before the earnings release to $41.97 the day after.
When is TG Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for TG Therapeutics, Inc.'s next earnings report?
Based on --
analysts, TG Therapeutics, Inc. is expected to report EPS of $0.35 and revenue of $231.11M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement